All you need to know about the peanut allergy race

Immunotherapy isn’t just for cancer. A pair of companies are vying to hit the market with treatments that tinker with the body’s natural defenses to keep kids with peanut allergies safe from dangerous accidental exposure.

But the supporting data leave quite a few questions unanswered.

That’s why we recruited Dr. Erwin Gelfand, a pediatric allergist at National Jewish Health in Denver, to be our guest for the next session of STAT Expert Advantage. Next month, we’ll talk to Gelfand about in-development treatments from Aimmune Therapeutics and DBV Technologies, the merits of their data, and what prescribing physicians want to see from a peanut allergy immunotherapy.

The live call is Aug. 28, and you can sign up right here.